An innovative algorithm,* using data from multiple international trials, has been developed to identify patients with ER positive, HER2 negative primary breast cancer, who have less endocrine-sensitive tumours so are less likely to respond to hormone therapy. These women can therefore be prioritised for early surgery or neoadjuvant chemotherapy.
The approach has been developed by researchers at The Royal Marsden and the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, in collaboration with colleagues elsewhere in the UK, and Germany and the US.
While patients diagnosed with triple negative or HER2 positive breast cancers have still been going forward for urgent surgery or chemotherapy, for a large group of patients with ER positive breast cancer, deferring these treatments and prescribing neoadjuvant hormone therapy (NeoET), i.e. treatment to reduce the stimulation of the disease by oestrogen to keep the disease under control without the surgical removal of the breast tumour, has been identified as the best course of treatment.